Tirzepatide

Generic Name: Tirzepatide

Brand Names: Mounjaro

Drug Type: Biotech

Chemical Formula: -

CAS Number: 2023788-19-2

Unique Ingredient Identifier: OYN3CCI6QE

Background: Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. Dual GIP/GLP-1 agonists gained increasing attention as new therapeutic agents for glycemic and weight control as they demonstrated better glucose control and weight loss compared to selective GLP-1 receptor agonists in preclinical and clinical trials.

Tirzepatide comprises a 39 amino acid linear synthetic peptide conjugated to a C20 fatty diacid moiety. Its protein sequence was based on the sequence of endogenous GIP, and its pharmacological action on GLP-1 receptors is comparable to endogenous GIP; however, the long half-life of tirzepatide allows for once-weekly dosing. Tirzepatide was approved by the FDA on May 13, 2022, for the treatment of adults with type 2 diabetes, making it the first and only GIP and GLP-1 receptor agonist for this indication. On September 15, 2022, tirzepatide was also approved by the European Commission.

Indication: Tirzepatide is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. In Europe, it may be used as monotherapy or in combination with other drugs used to treat diabetes.

This drug has not been studied in patients with a history of pancreatitis. Tirzepatide is not indicated for use in patients with type 1 diabetes mellitus.

Associated Conditions: Type 2 Diabetes Mellitus

Associated Therapies: -

Clinical Trials

Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide

Phase 4

Not yet recruiting

Conditions: Diabetes Mellitus, Type 2

Interventions: Procedure: Insulin resistance testing
Procedure: OGTT
Procedure: Fat biopsy
Radiation: DXA scan
Procedure: MRI
Procedure: 1H-MRS
Drug: Tirzepatide
Drug: Pioglitazone

First Posted Date: 2024-10-24

Last Posted Date: 2024-10-24

Lead Sponsor: Stanford University

Target Recruit Count: 104

Registration Number: NCT06657209

Locations: 🇺🇸
Stanford University, Clinical and Translational Research Unit (CTRU), Stanford, California, United States

Evaluation of Tirzepatide As an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

Phase 2

Not yet recruiting

Conditions: Opioid Use Disorder
Opioid Use Disorder, Moderate
Opioid Use Disorder, Severe

Interventions: Drug: Tirzepatide
Other: Placebo

First Posted Date: 2024-10-21

Last Posted Date: 2024-10-21

Lead Sponsor: T. John Winhusen, PhD

Target Recruit Count: 310

Registration Number: NCT06651177

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Phase 2

Recruiting

Conditions: Obesity
Overweight

Interventions: Drug: Tirzepatide
Drug: Bimagrumab
Drug: Placebo

First Posted Date: 2024-10-16

Last Posted Date: 2025-01-06

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 140

Registration Number: NCT06643728

Locations: 🇺🇸
Pinnacle Research Group, LLC, Anniston, Alabama, United States
🇺🇸
Central Research Associates, Birmingham, Alabama, United States
🇺🇸
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare, Jacksonville, Florida, United States

and more 7 locations

A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan

Phase 4

Not yet recruiting

Conditions: Type 2 Diabetes

Interventions: Drug: Tirzepatide

First Posted Date: 2024-10-10

Last Posted Date: 2024-10-10

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 180

Registration Number: NCT06635057

Locations: 🇸🇦
Al Moosa Hospital, Al Mubarraz, Al-Ahsa, Saudi Arabia

GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes

Phase 3

Not yet recruiting

Conditions: Type 1 Diabetes (T1D)

Interventions: Drug: Tirzepatide

First Posted Date: 2024-10-08

Last Posted Date: 2024-10-18

Lead Sponsor: University of Bern

Target Recruit Count: 42

Registration Number: NCT06630585

Locations: 🇨🇭
Kantonsspital Olten, Olten, Solothurn, Switzerland

The Effects of Tirzepatide in People with Overweight/obesity and Coronary Artery Disease

Phase 4

Recruiting

Conditions: Coronary Artery Disease
Coronary Microvascular Dysfunction
Overweight or Obesity
Stable Angina Pectoris
Chronic Coronary Artery Disease
Atherosclerosis Cardiovascular Disease

Interventions: Drug: Tirzepatide
Drug: Placebo

First Posted Date: 2024-09-23

Last Posted Date: 2024-09-23

Lead Sponsor: Tina Vilsbøll

Target Recruit Count: 124

Registration Number: NCT06606821

Locations: 🇩🇰
Rigshospitalet, Copenhagen, Denmark
🇩🇰
Gentofte Hospital, Gentofte, Denmark
🇩🇰
Steno Diabetes Center Copenhagen, Herlev, Denmark

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Phase 2

Recruiting

Conditions: Obesity
Overweight

Interventions: Drug: LY3841136
Drug: Tirzepatide
Drug: Placebo

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 350

Registration Number: NCT06603571

Locations: 🇺🇸
Diablo Clinical Research, Inc., Walnut Creek, California, United States
🇦🇷
Centro Médico Viamonte, Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina
🇦🇷
Centro Medico Dra. Laura Maffei- Investigacion Clinica Aplicada, Ciudad Autonoma de Buenos Aires, Ciudad Autónoma De Buenos Aires, Argentina

and more 48 locations

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

Phase 3

Recruiting

Conditions: Psoriatic Arthritis
Obesity

Interventions: Drug: Ixekizumab
Drug: Tirzepatide

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 250

Registration Number: NCT06588296

Locations: 🇺🇸
Willow Rheumatology and Wellness PLLC, Willowbrook, Illinois, United States
🇺🇸
Research Physicians Network, LLC, Houston, Texas, United States
🇺🇸
Biopharma Informatic, LLC, Katy, Texas, United States

and more 84 locations

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight

Phase 3

Recruiting

Conditions: Psoriasis
Obesity

Interventions: Drug: Ixekizumab
Drug: Tirzepatide

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 250

Registration Number: NCT06588283

Locations: 🇺🇸
NeoClinical Research, Hialeah, Florida, United States
🇺🇸
Skin Care Research, Hollywood, Florida, United States
🇺🇸
Encore Medical Research, Hollywood, Florida, United States

and more 71 locations

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide with Tirzepatide for the Treatment of Obesity

Phase 2

Active, not recruiting

Conditions: Obesity

Interventions: Drug: bremelanotide
Drug: tirzepatide

First Posted Date: 2024-08-22

Last Posted Date: 2025-01-08

Lead Sponsor: Palatin Technologies, Inc

Target Recruit Count: 108

Registration Number: NCT06565611

Locations: 🇺🇸
University Clinical Research-DeLand LLC, d/b/a Accel Research, DeLand, Florida, United States
🇺🇸
Lynn Health Science Institute, Oklahoma City, Oklahoma, United States
🇺🇸
Coastal Carolina Research Center, North Charleston, South Carolina, United States

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy